Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
暂无分享,去创建一个
An Carbonez | Paul Rutgeerts | P. Rutgeerts | S. Vermeire | F. Baert | M. Noman | G. Van Assche | Filip Baert | Maja Noman | Severine Vermeire | Gert Van Assche | Geert D' Haens | A. Carbonez | G. D' Haens
[1] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[2] M. Pfreundschuh,et al. The future of monoclonal antibody engineering , 2001, Annals of Hematology.
[3] R. Cohen. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. , 2001, Inflammatory bowel diseases.
[4] M. Peppercorn,et al. Human anti-chimeric antibody levels correlate with lack of response and infusion reactions following infliximab therapy , 2001 .
[5] W. Sandborn,et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients , 2000, American Journal of Gastroenterology.
[6] U. Klotz,et al. Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease , 2001, Clinical pharmacokinetics.
[7] S. Hanauer,et al. Infliximab in Crohn's disease: first anniversary clinical experience , 2000, American Journal of Gastroenterology.
[8] Samir A. Shah,et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease , 2000, American Journal of Gastroenterology.
[9] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[10] M. Clark,et al. Antibody humanization: a case of the 'Emperor's new clothes'? , 2000, Immunology today.
[11] F. Breedveld,et al. Therapeutic monoclonal antibodies , 2000, The Lancet.
[12] S. Hanauer. Safety of infliximab in clinical trials , 1999 .
[13] E. Vasiliauskas,et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.
[14] S. Hanauer. Review article: safety of infliximab in clinical trials , 1999, Alimentary pharmacology & therapeutics.
[15] P. Rutgeerts,et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.
[16] F. Breedveld,et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[17] R. Hamilton,et al. Humanized antibodies as potential therapeutic drugs. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[18] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .